Clinical Trial

Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

Completed
View on ClinicalTrials.gov →
Summary
For participation in this epidemiological study, a single-day visit at the study site is required. Participants will be recruited from Huntington Disease clinics, and they will be asked to answer questions regarding their demographics, including sex, age, race and ethnicity, and their medical and medication history. At the end of the visit, a blood sample will be drawn to allow testing with a sequencing assay that is specifically designed for phasing single nucleotide polymorphisms (SNPs) on the wild-type Huntington (wtHTT) and mutant Huntington (mHTT) alleles.
Protocol Amendment History 5 changes
critical Trial completed 2026-07-29
notable Primary completion moved earlier: 2027-02-28 -> 2026-07-03 2026-07-29
minor Completion moved earlier: 2027-02-28 -> 2026-07-03 2026-07-29
notable Primary completion moved earlier: 2028-09-24 -> 2027-02-28 2026-04-30
minor Completion moved earlier: 2028-09-24 -> 2027-02-28 2026-04-30
Trial Details
NCT Number NCT06667414
Lead Sponsor Hoffmann-La Roche
Conditions Huntington Disease
Enrollment 574 participants
Start Date 2024-09-02
Primary Completion 2026-07-03 (estimated)
Study Completion 2026-07-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-28